Get started
Author

GC Carter

Institutions: Universidad Complutense de Madrid, Royal Marsden NHS Foundation Trust, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Eli Lilly (United States), University of California, San Francisco, Universität Ulm, Baylor University Medical Center, National Hospital Organization Kyushu Cancer Center, Sarah Cannon, Dana-Farber Cancer Institute, National Cancer Center, Tennessee Oncology, Kyoto University Hospital, Flatiron Health (United States), Hospital Universitario Ramón y Cajal, Vall d'Hebron Institute of Oncology, Instituto de Investigación Sanitaria Gregorio Marañón
Observed institutions: Universidad Complutense de Madrid, Royal Marsden NHS Foundation Trust, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Eli Lilly (United States), University of California, San Francisco, Universität Ulm, Baylor University Medical Center, National Hospital Organization Kyushu Cancer Center, Sarah Cannon, Dana-Farber Cancer Institute, National Cancer Center, RTI Health Solutions, Tennessee Oncology, Kyoto University Hospital, Flatiron Health (United States), Hospital Universitario Ramón y Cajal, Vall d'Hebron Institute of Oncology, Instituto de Investigación Sanitaria Gregorio Marañón
OpenAlex ID: A5088890977
Abstract P6-16-01: Health-related quality of life in MONARCH 3: Abemaciclib plus an aromatase inhibitor as initial therapy in women with HR+, HER2- advanced breast cancer
2019 · MP Goetz, S Johnston, et al. · Cancer Research · 2
Abstract P6-18-19: Real-world survival of heavily pretreated patients with refractory HR+, HER2- metastatic breast cancer receiving single-agent chemotherapy - A comparison with MONARCH 1
2019 · H Rugo, V Dieras, et al. · Cancer Research
Abstract P2-08-38: Influence of prognostic factors on outcomes among metastatic breast cancer patients treated with CDK4&6 inhibitors in routine clinical practice
2019 · KR Saverno, GC Carter, et al. · Cancer Research
Abstract P5-08-18: Treatment patterns and resource utilization among patients with HR+/HER2– metastatic breast cancer in a privately insured US population
2017 · RK Goyal, GC Carter, et al. · Cancer Research
Abstract P5-08-19: Treatment patterns and resource utilization among elderly Medicare patients with HR+/HER2– metastatic breast cancer
2017 · RK Goyal, GC Carter, et al. · Cancer Research
Wirksamkeit und Sicherheit der Kombination Ramucirumab (RAM) plus Docetaxel (DOC) versus Placebo (PL) plus DOC bei Patienten mit vorbehandeltem nicht plattenepithelialen nicht kleinzelligen Lungenkarzinom (NSCLC): explorative Analyse der REVEL Studie (RAM plus DOC versus PL plus DOC in der Zweitlinientherapie des NSCLC im Stadium IV)
2016 · M Reck, L Paz-Ares, et al. · Pneumologie
Update REVEL: Eine randomisierte, doppelblinde Phase III Studie von Docetaxel (DOC) und Ramucirumab (RAM; IMC-1121B) versus DOC und Placebo (PL) in der Zweitlinienbehandlung des Nicht-Kleinzelligen Lungenkarzinoms im Stadium IV nach Progression der Erkrankung nach einer Platin-basierten Vortherapie
2015 · M Reck, M Thomas, et al. · Pneumologie
Works count: 7
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type